'김갑성' 기자의 전체기사
-
Fapon to Showcase Innovative Molecular Diagnostic Solutio…
BOSTON, Nov. 10, 2025 -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo during November 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics that power qPCR/RT-qPCR, Isothermal Amplification, and Next-Generation Sequencing (NGS) library preparation. By integrating AI-driven design and high-throughput assays, Fapon actively leverages its AI-enabled enzyme engineering platform to improve product performance. Its showcased enzymes and reagents are engineered to enhance the accuracy, efficiency, and rel
- 김갑성 기자
- 2025-11-10 20:30
-
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II C…
NANJING, China, Nov. 10, 2025 -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in China for the treatment of moderate-to-severe atopic dermatitis (AD). The first dose was achieved in Hangzhou First People's Hospital. This randomized, double-blind, placebo-controlled, multi-center Phase II study is aiming to evaluate the efficacy, safety, and pharmacokinetics of continuous subcutaneous administration of SIM0278 in participants with moder
- 김갑성 기자
- 2025-11-10 20:06
-
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in…
SEOUL, South Korea, Nov. 10, 2025 -- LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 clinical trial of LB-P8, a novel therapeutic candidate for Primary Sclerosing Cholangitis (PSC), a rare and progressive liver disease with no approved treatments on November 5 (local time in the U.S.). LB-P8: A First in Class Candidate Targeting the Gut-Liver axis PSC is a cholestatic liver disease of unknown etiology, characterized by inflammation and fibrosis of the bile d
- 김갑성 기자
- 2025-11-10 20:00
-
Akeso Announces First Patient Dosed in Phase I Trial of Pers…
HONG KONG, Nov. 10, 2025 -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the company's first-in-class bispecific antibodies, cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), for the adjuvant treatment of pancreatic cancer following surgical resection. AK154 is Akeso's first mRNA-based therapeutic candidate to enter clinical development. This achievement marks a significant breakth
- 김갑성 기자
- 2025-11-10 19:39
-
MediTrust Health and Sino Biopharm Sign Strategic Cooperat…
HONG KONG, Nov. 10, 2025 -- Shanghai, November 10, 2025 – During the 8th China International Import Expo (CIIE), Sino Biopharmaceutical Limited ("Sino Biopharm") and Shanghai MediTrust Health Technology Group Co., Ltd. ("MediTrust Health") signed a strategic cooperation agreement. The two parties will carry out in-depth cooperation around innovative drugs and commercial insurance, jointly explore a new model of drug-insurance integration, and help more patients access high-quality, affordable medicines at an earlier stage. Mr. Tse Hsin, Executive Director an
- 김갑성 기자
- 2025-11-10 14:18
-
Jiahui International Cancer Center Attracts Global Patients with…
SHANGHAI, Nov. 10, 2025 -- On November 7, Jiahui International Cancer Center (JICC) successfully treated a 78-year-old patient from New Zealand with relapsed multiple myeloma using CAR-T therapy, highlighting JICC's growing reputation as a destination for cutting-edge oncology care for international patients. The patient received Zevor-cel (Zevor-cel Injection) CAR-T therapy and was discharged in stable condition. The patient, a retired family medicine doctor with 40 years of experience, had exhausted all conventional treatment options in his home country. Following a recommendation fr
- 김갑성 기자
- 2025-11-10 14:09
-
Rona Therapeutics Presents Phase 1 Data for RN0361, a Lon…
NEW ORLEANS, Nov. 10, 2025 -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved potent, durable reductions in ApoC3 and triglycerides (TG) lasting at least six months in a single dose first-in-human trial, establishing a potential best-in-class profile to prevent pancreatitis in severe hypertriglyceridemia (HTG) and reduce cardiovascular risk (CVD) from atherogenic lipoproteins. The data were presented today at the American Heart Associatio
- 김갑성 기자
- 2025-11-10 12:00
-
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotec…
CHENGDU, China, Nov. 10, 2025 -- From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association (CACA), the Tengchong Science Forum Organizing Committee Office, the World Association for Integrative Oncology (WAIO), and the China Institute for Integrative Medicine Development Strategy. Academicians, experts, and scholars from across the nation gathered to focus on innovations in cancer diagnosis and treatment while sharing scientific breakthroughs. At the
- 김갑성 기자
- 2025-11-10 10:01
-
ICP DAS-BMP Attends MOU Signing Ceremony to Mark a New Milesto…
HSINCHU, Nov. 10, 2025 -- ICP DAS-BMP participated in the Strategic Memorandum of Understanding (MOU) signing ceremony organized by Towards Buddha Co., Ltd. on October 28, where it showcased its R&D achievements and diverse applications in medical-grade TPU materials. Moving forward, ICP DAS-BMP will collaborate with industry experts and think-tank teams to foster innovation and jointly drive the development and wider adoption of TPU materials in global markets. The event brought together industry partners including ICP DAS CO., LTD. / ICP DAS-BMP, Intype Enterprise
- 김갑성 기자
- 2025-11-10 08:45
-
ICP DAS-BMP, 의료용 TPU 소재의 새로운 이정표 위한 MOU 체결식에 참석
신주 2025년 11월 10일 -- ICP DAS-BMP가 지난 10월 28일 투워드 부다((Toward Buddha Co., Ltd.)가 주최한 전략적 양해각서(MOU) 체결식에 참석해 의료용 TPU(열가소성 폴리우레탄) 소재의 연구개발 성과와 다양한 응용 분야를 선보였다. 향후 ICP DAS-BMP는 업계 전문가 및 싱크탱크 팀과 협력해 혁신을 촉진하고, TPU 소재의 개발과 글로벌 시장 확산을 공동으로 추진할 예정이다. 이번 행사에는 ICP DAS CO., LTD. / ICP DAS-BMP, 인타입 엔터프라이즈(Intype Enterprise Co., Ltd.), 에이-맥스 테크놀로지(A-MAX Technology Co., Ltd.), 메드서브 바이오텍(MedServ Biotech Co., Ltd.), 레온 바이오텍(LEON Biotech Co., Ltd.), 볼러 바이오텍 컨설팅(VOLER Biotech Consulting Co., Ltd.), 치펑(Chi Feng Co., Ltd.), 투워즈버다(Toward Buddha Co., Ltd.) 등 업계 주요 파트너들이 참석했다. 이들 기업은 의료용
- 김갑성 기자
- 2025-11-10 08:45
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-12-11_THU
- ADI 재단, ADI 체인 메인넷 및 ADI 유틸리티 토큰 출시 02:31
- ADFW's Fintech Abu Dhabi Points to a New Era of Finance Fuelled by Innovation and Disruption 02:02
- カタール博物館のTasweer 、「文化の年（Years of Culture）」の一環として「一つの空の下（Under One Sky）」世界写真公募を発表 00:54
- 카타르 박물관 타스위르, '같은 하늘 아래' 국제 사진 공모전 개최 00:29
2025-12-10_WED
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 12월 11일 04시 00분